AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15761754 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of enalaprilat
Number of subjects: 40
Study 15761754 — intervention group
Group type: COMPARATOR
Intervention: Low concentration of enalaprilat
Number of subjects: 40
Study 12082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 5 mg/day
Number of subjects: 23
Study 12082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized, oil-suspended progesterone 200 mg/day
Number of subjects: 23
Study 12082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined progestogens (MPA and progesterone)
Number of subjects: 23
Study 12082361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10207208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal cord paresis (VCP) in acute ischemic stroke patients
Number of subjects: 54
Study 10207208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonia correlation
Number of subjects: 54
Study 10207208 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of VCP
Number of subjects: 54
Study 8701750 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A (Hup) 0.2 mg (4 tablets) orally, twice daily for 8 weeks
Number of subjects: 103
Study 8701750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 tablets) orally, twice daily for 8 weeks
Number of subjects: 103
Study 2140961 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (1.95 pmol/min per kg)
Number of subjects: 0
Study 2140961 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg, administered orally) with physiological saline (placebo)
Number of subjects: 0
Study 158752 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 77
Study 158752 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 77
Study 31289040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab (peri-operative immunotherapy)
Number of subjects: 0
Study 31289040 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27988849 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) and antibiotic treatment after surgical debridement
Number of subjects: 115
Study 25474553 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily)
Number of subjects: 523
Study 25474553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 23894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping 70% isopropyl alcohol at the site of venipuncture
Number of subjects: 52
Study 23894865 — intervention group
Group type: COMPARATOR
Intervention: Not wiping 70% isopropyl alcohol at the site of venipuncture
Number of subjects: 52
Study 21646599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily (N=65)
Number of subjects: 128
Study 21646599 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 95 mg once daily (N=63)
Number of subjects: 128
Study 19344465 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and strength training (SET)
Number of subjects: 43
Study 19344465 — intervention group
Group type: COMPARATOR
Intervention: No-training (NT)
Number of subjects: 43
Study 16410677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (1 mg/day) + Clarithromycin (400 mg/day) for 6 days
Number of subjects: 17
Study 16410677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (stable doses) + Clarithromycin (400 mg/day) for 6 days
Number of subjects: 17
Study 16410677 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline (1 mg/day) for 6 days
Number of subjects: 17
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus sealer with smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit sealer with smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 811 sealer with smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus sealer without smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit sealer without smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 811 sealer without smear layer
Number of subjects: 64
Study 14977306 — intervention group
Group type: COMPARATOR
Intervention: Control group A (smear layer intact)
Number of subjects: 64
Study 14977306 — intervention group
Group type: COMPARATOR
Intervention: Control group B (smear layer removed)
Number of subjects: 64
Study 11306204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens 0.625 mg/day for 28 days plus MAP 10 mg/day for the last 14 days
Number of subjects: 50
Study 11306204 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol 50 mcg every 7 days for 28 days plus MAP 10 mg/day from 15th to 28th day
Number of subjects: 50
Study 9272341 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 10771
Study 9272341 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine
Number of subjects: 10771
Study 9272341 — intervention group
Group type: EXPERIMENTAL
Intervention: DT vaccine
Number of subjects: 10771
Study 9217687 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia-hypoglycaemia-euglycaemia treatment order
Number of subjects: 0
Study 9217687 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia-placebo(euglycaemia)-euglycaemia treatment sequence
Number of subjects: 0
Study 2547305 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine/cis‐platin
Number of subjects: 152
Study 2547305 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide/cis‐platin
Number of subjects: 152
Study 2547305 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine/etoposide/cis‐platin
Number of subjects: 152
Study 2547305 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐platin/vindesine/etoposide
Number of subjects: 152
Study 973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (2.5 mg)
Number of subjects: 12
Study 973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 12
Study 973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium (50 mg)
Number of subjects: 12
Study 973963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium (100 mg)
Number of subjects: 12
Study 973963 — intervention group
Group type: COMPARATOR
Intervention: Lactose (Control)
Number of subjects: 12
Study 973963 — intervention group
Group type: EXPERIMENTAL
Intervention: All active drugs
Number of subjects: 12
Study 31226412 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive linkage with NCMS claims data
Number of subjects: 33948
Study 31226412 — intervention group
Group type: COMPARATOR
Intervention: Active follow-up
Number of subjects: 33948
Study 28830428 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy 1 (oligofructose-enriched inulin) 10 g daily
Number of subjects: 34
Study 28830428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 34
Study 25253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan combined with a calcium channel blocker (CCB)
Number of subjects: 5141
Study 25253582 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan combined with a diuretic
Number of subjects: 5141
Study 23675705 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dancing (ballroom or folk dance)
Number of subjects: 450
Study 23675705 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control
Number of subjects: 450
Study 21939829 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income <$20,000
Number of subjects: 26160
Study 21939829 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than a high school education
Number of subjects: 26160
Study 21939829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest income levels
Number of subjects: 26160
Study 21939829 — intervention group
Group type: EXPERIMENTAL
Intervention: Least amount of education
Number of subjects: 26160
Study 19801053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (STG)
Number of subjects: 24
Study 19801053 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CRG)
Number of subjects: 24
Study 16685296 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 14
Study 16685296 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 14
Study 15385015 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0‐1 microg x kg(‐1) x min(‐1))
Number of subjects: 20
Study 15385015 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (30 microg x kg(‐1)) plus morphine (1 mg x kg(‐1))
Number of subjects: 20
Study 15385015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 11259471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (adjuvant arm) for 5 years
Number of subjects: 1323
Study 11259471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (duration trial) continued indefinitely
Number of subjects: 1323
Study 11259471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (duration trial) stopped after 5 years
Number of subjects: 1323
Study 9223734 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine (ZVD) therapy
Number of subjects: 1749
Study 8093681 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 10
Study 8093681 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 3072419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (80 mg daily)
Number of subjects: 24
Study 3072419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30324834 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole with luteal support using vaginal dydrogesterone (n = 94)
Number of subjects: 186
Study 30324834 — intervention group
Group type: COMPARATOR
Intervention: letrozole alone (n = 92)
Number of subjects: 186
Study 28169927 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recording and replaying system
Number of subjects: 60
Study 28169927 — intervention group
Group type: COMPARATOR
Intervention: Conventional training method
Number of subjects: 60
Study 26526507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (5‐10mg/kg daily divided into 2 doses)
Number of subjects: 30
Study 26526507 — intervention group
Group type: COMPARATOR
Intervention: Local steroids
Number of subjects: 30
Study 23612730 — intervention group
Group type: EXPERIMENTAL
Intervention: MediGuide Technology
Number of subjects: 24
Study 23612730 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional ablation)
Number of subjects: 24
Study 21697629 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior pelvic tilt taping (APTT)
Number of subjects: 0
Study 21697629 — intervention group
Group type: COMPARATOR
Intervention: No anterior pelvic tilt taping (no-APTT)
Number of subjects: 0
Study 18094011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention focused on improving inhalation technique and medication adherence
Number of subjects: 201
Study 18094011 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacist care
Number of subjects: 201
Study 18094011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 201
Study 16198027 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ISS (0, 8 weeks)
Number of subjects: 99
Study 16198027 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (0, 8, 24 weeks)
Number of subjects: 99
Study 16198027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 16198027 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ISS
Number of subjects: 99
Study 12974594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil infusion
Number of subjects: 88
Study 12974594 — intervention group
Group type: EXPERIMENTAL
Intervention: Boluses of fentanyl with a propofol infusion
Number of subjects: 88
Study 12974594 — intervention group
Group type: EXPERIMENTAL
Intervention: Boluses of fentanyl and midazolam
Number of subjects: 88
Study 11885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Top Performance Group (TPG) implants
Number of subjects: 2900
Study 11885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Performance Group (MPG) implants
Number of subjects: 2900
Study 11885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Performance Group (LPG) implants
Number of subjects: 2900
Study 11885172 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated cylinder implants
Number of subjects: 2900
Study 11885172 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially pure titanium screw implants
Number of subjects: 2900
Study 8832445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 million KIU of aprotinin over 20 minutes
Number of subjects: 40
Study 8832445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 1349184 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of worms (treatment)
Number of subjects: 159
Study 1349184 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninfected)
Number of subjects: 159
Study 6146995 — intervention group
Group type: EXPERIMENTAL
Intervention: cis(Z)-clopenthixol decanoate
Number of subjects: 8
Study 6146995 — intervention group
Group type: EXPERIMENTAL
Intervention: fluphenazine decanoate
Number of subjects: 8
Study 31500466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin treatment
Number of subjects: 0
Study 31500466 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (placebo control)
Number of subjects: 0
Study 31500466 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (survivors)
Number of subjects: 0
Study 30324975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) - 8 sessions, 10 min each at 11-12 °C
Number of subjects: 20
Study 30324975 — intervention group
Group type: COMPARATOR
Intervention: No Cold Water Immersion (no-CWI) - control group
Number of subjects: 20
Study 26284383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical activity intervention for 6 months
Number of subjects: 20
Study 26284383 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 26284383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical activity intervention
Number of subjects: 20
Study 24280639 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in emotion understanding (conversations on emotion understanding after reading illustrated scenarios)
Number of subjects: 110
Study 24280639 — intervention group
Group type: COMPARATOR
Intervention: Control group (producing a drawing about the story)
Number of subjects: 110
Study 22494796 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) treatment
Number of subjects: 18
Study 22494796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20142601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 299
Study 20142601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 299
Study 20142601 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 299
Study 18568921 — intervention group
Group type: EXPERIMENTAL
Intervention: BodySense intervention program (3-month duration)
Number of subjects: 62
Study 18568921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 16496604 — intervention group
Group type: EXPERIMENTAL
Intervention: HA Biocer implants
Number of subjects: 51
Study 16496604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 11868925 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally collected, unpasteurized, unfiltered honey
Number of subjects: 36
Study 11868925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationally collected, filtered, and pasteurized honey
Number of subjects: 36
Study 11868925 — intervention group
Group type: COMPARATOR
Intervention: Corn syrup with synthetic honey flavoring (placebo)
Number of subjects: 36
Study 10520795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug (AAD)
Number of subjects: 0
Study 10520795 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 0
Study 8616478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialic acid concentration in bronchoalveolar lavage fluid (BALF) in patients with interstitial pulmonary diseases
Number of subjects: 187
Study 8616478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialic acid concentration in BALF in patients with avian fanciers lung
Number of subjects: 187
Study 8616478 — intervention group
Group type: COMPARATOR
Intervention: Sialic acid concentration in BALF
Number of subjects: 187
Study 2285641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice daily)
Number of subjects: 12
Study 2285641 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice daily)
Number of subjects: 12
Study 2285641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin plus Captopril (both at specified dosages)
Number of subjects: 12
Study 2285641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7175506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information processing training for approximately seven weeks
Number of subjects: 153
Study 7175506 — intervention group
Group type: COMPARATOR
Intervention: Contrast group with small group instruction using regular curriculum materials
Number of subjects: 153
Study 7175506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information processing training
Number of subjects: 153
Study 30854868 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-day wellbeing workshop
Number of subjects: 0
Study 30854868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation every month for 12 months
Number of subjects: 58
Study 28905421 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 58
Study 28905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 58
Study 25452050 — intervention group
Group type: EXPERIMENTAL
Intervention: High affirmation
Number of subjects: 203
Study 25452050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low affirmation
Number of subjects: 203
Study 25452050 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking image control
Number of subjects: 203
Study 25452050 — intervention group
Group type: COMPARATOR
Intervention: Smoking image control
Number of subjects: 203
Study 23617687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent pharmaceutical care intervention (patient interview, pharmacotherapy review, execution and follow-up evaluation of a pharmaceutical care plan)
Number of subjects: 674
Study 23617687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent pharmaceutical care intervention
Number of subjects: 674
Study 23617687 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 674
Study 21334200 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 8873
Study 21334200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 8873
Study 19466943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized sextant prostate biopsies
Number of subjects: 1305
Study 19466943 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA level
Number of subjects: 1305
Study 19466943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate volume (Pvol)
Number of subjects: 1305
Study 19466943 — intervention group
Group type: COMPARATOR
Intervention: Larger Pvol
Number of subjects: 1305
Study 17526934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 9
Study 17526934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 9
Study 17526934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day and 80 mg/day
Number of subjects: 9
Study 17526934 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 9
Study 17526934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15542205 — intervention group
Group type: EXPERIMENTAL
Intervention: HibCRM197 vaccine (doses > or =1.25 microg)
Number of subjects: 0
Study 15542205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-tetanus vaccine (doses > or =1.25 microg)
Number of subjects: 0
Study 11251436 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 10 mg.s-1
Number of subjects: 40
Study 11251436 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion at 2 mg.s-1
Number of subjects: 40
Study 9512842 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 30 mg before induction of anaesthesia
Number of subjects: 61
Study 9512842 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 30 mg 20 min after skin incision
Number of subjects: 61
Study 9512842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7801058 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID cream (DOLGIT cream)
Number of subjects: 11
Study 7801058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3078156 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized antiarrhythmic therapy (mexiletine or quinidine)
Number of subjects: 238
Study 3078156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone (200-400 mg/day after a loading phase)
Number of subjects: 238
Study 3078156 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 238
Study 29146139 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental nutrition drinks (250 kcal/day) for HIV-positive hemodialysis patients (Group 1)
Number of subjects: 23